stockrowImmunityBio, Inc.
IBRX Healthcare Biotechnology
ImmunityBio, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $113.3 million, up 668.3% from fiscal 2024.
- Revenue
- +93.9%
- EPS
- −120.0%
- Free cash flow
- +13.4%
- Total debt
- +57.4%
Quarter to June 2026, against a year earlier
Follow IBRX
Alert me
ImmunityBio, Inc. (IBRX) Book value per share
ImmunityBio, Inc.'s book value per share at the end of fiscal 2025 was −0.5×, compared with −0.7× in fiscal 2024. At the end of the quarter to 30 June 2026 it was −1.0×. Over the past ten years it has ranged from −1.2× (fiscal 2023) to 5.0× (fiscal 2015); the current reading is higher than 45% of that period. ImmunityBio, Inc. ranks 567th of 611 Biotechnology companies by book value per share.
Book value per share, annual
Embed this chart
Annual newest first
| Period | Book value per share | Change |
|---|---|---|
| FY2025 | −0.5× | — |
| FY2024 | −0.7× | — |
| FY2023 | −1.2× | — |
| FY2022 | −1.1× | — |
| FY2021 | −0.6× | — |
| FY2020 | −0.3× | — |
| FY2019 | 0.3× | (82.15%) |
| FY2018 | 1.8× | (32.06%) |
| FY2017 | 2.7× | (24.13%) |
| FY2016 | 3.6× | (28.09%) |
Quarterly newest first
| Period | Book value per share | Change |
|---|---|---|
| Jun 2026 | −1.0× | — |
| Mar 2026 | −0.8× | — |
| Dec 2025 | −0.5× | — |
| Sep 2025 | −0.6× | — |
| 42 more quarters | Free account |
Against its own ten years
Book value per share against peers
| Company | Book value per share |
|---|---|
| KRYS Krystal Biotech, Inc. compare | 48.5× |
| MDGL Madrigal Pharmaceuticals, Inc. compare | 21.4× |
| PTGX Protagonist Therapeutics, Inc. compare | 12.8× |
| SYRE Spyre Therapeutics, Inc. compare | 11.9× |
| TWST Twist Bioscience Corporation compare | 7.1× |
| TGTX TG Therapeutics, Inc. compare | 4.3× |
| CYTK Cytokinetics, Incorporated compare | 0.0× |
| CAI Caris Life Sciences,�Inc. compare | 0.0× |
| IBRX ImmunityBio, Inc. | −1.0× |
What Book value per share is
BV per Share tells an investor how much of a company’s accounting net worth stands behind each share.
(Shareholders Equity (Total) ÷ Shares (Basic, Weighted))
More on IBRX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement